Psychopharmacologic Drugs Advisory Committee
New Drug Application (NDA)
20-717/ S -019, trade name Provigil® Tablets, Cephalon, Inc., proposed
indication is for treatment of attention-deficit/ hyperactivity disorder
(ADHD).
ERRATA to the Transcript
On page 47, line 1: “the
0.7 would still be statistically significant” should read “the 0.07 would still be statistically
significant”
On page 51, line 7: “that is with 1.5 million” should read “that
is with 1,050,000”